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Abstract
Background. p27kip1 is a tumour suppressor gene, functioning as a cyclin-dependent kinase inhibitor, and an independent
prognostic factor in breast, colon, and prostate adenocarcinomas. Conflicting data are reported for adenocarcinoma of the
pancreas. The aim of this study was to establish the prognostic value of p27kip1 expression in adenocarcinoma of the
pancreatic head region. Patients and methods. The study included 45 patients (male/female ratio 2:1; mean age 59, range
3882 years) with adenocarcinomas of the pancreatic head region: 24  pancreatic head, 18  periampullary and 3 
uncinate process. The patients underwent the Kausch-Whipple pancreatoduodenectomy (n/39), pylorus-preserving
pancreatoduodenectomy (n/5), or nearly total pancreatectomy (n/1). Eight patients received adjuvant chemotherapy
postoperatively. Follow-up time ranged from 3 to 60 months. Tumours were staged according to the pTNM classification
(UICC 1997). Immunohistochemistry was done on paraffin-embedded blocks from tumour sections. Quantitative
determination of p27kip1 expression was based on the proportion of p27kip1 -positive cells (B/5%/negative). Survival
analysis was carried out using the Kaplan-Meier method and Cox regression model. Results. Positive p27kip1 expression was
detected in 22 tumours (49%), whereas 23 tumours (51%) were p27kip1-negative. There were no significant correlations
between p27kip1 index and stage or lymph node involvement. Median survival time in patients with p27kip1-positive tumours
was 19 months, whereas in patients with p27kip1-negative tumours it was 18 months (p/0.53). A significant relationship
was found between p27kip1-negative tumours and radical resection (p/0.04). Multivariate survival analysis revealed that
the localization of the tumour (pancreatic head/uncinate process vs periampullary) was the only significant and independent
prognosticator (p/ 0.01, Cox regression model). Resection margins involvement and grade remained nearly significant
prognostic factors (p/0.07 and p/0.09, respectively). Conclusion. We conclude that p27kip1 has limited overall prognostic
utility in resected carcinoma of the pancreatic head region, but its potential role as a marker of residual disease needs to be
further assessed.
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Introduction
The incidence of pancreatic carcinoma has increased
during recent decades, and it is the fourth most
common cause of cancer-related mortality [1,2].
Early systemic dissemination and local cancer pro-
gression are limitations of curative treatment [3].
Overall cumulative 5-year survival is extremely poor
(0.41%), and after curative resection is only 515%
[47]. Pathological stage, histological differentiation,
localization of the tumour and involved margins are
known prognostic factors [813].
The serum concentration of CA 242, CA 19.9 and
MUC1 markers may have the same prognostic
significance only in advanced pancreatic cancer [14
16]. Additional molecular prognosticators, such as
p53, cyclin D1, matrix metalloproteinase 1, vascular
endothelial growth factor, transforming growth factor
beta and DNA ploidy have also been described [17
22].
Neoplastic cells progress rapidly through the cell
cycle, often ignoring the cell division control mechan-
isms. Cyclin-dependent kinase (CDK) plays an im-
portant role in cell cycle control. p27kip1 is a putative
tumour suppressor gene and p27kip1 protein is re-
garded as an inhibitor of the G1-to-S cell cycle pro-
gression by suppressing the kinase activity of cyclin/
cyclin-dependent kinase inhibitor family (D-CDK4
and E-CDK2). In addition, p27 is a regulator of drug
resistance in solid tumours and promoter of apoptosis
[2325]. It has been characterized as an independent
prognostic factor in breast, colon, and prostate
adenocarcinomas [26]. There are conflicting data on
the prognostic significance of p27 expression in
adenocarcinoma of the pancreas [27,28].
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The aim of this study was to establish the prog-
nostic value of p27kip1 expression in adenocarcinoma
of the pancreatic head region following surgical
treatment.
Patients and methods
Patients and tumour samples
Between October 1998 and December 2003, 59
consecutive patients with histologically verified pan-
creatic adenocarcinoma and one patient with cysta-
denocarcinoma underwent resection. Tissue
specimens were evaluated only from 45 patients with
proven adenocarcinoma of the pancreatic head region:
24 (53%) pancreatic head, 18 (40%) periampullary
and three (7%) uncinate process (male/female ratio
2:1; mean age9/SD, 59.49/11.8, range 3882 years).
The patients underwent Kausch-Whipple pancrea-
toduodenectomy (n/39, 87%), Travesrso-Longmire
pylorus-preserving pancreato-duodenectomy (n/5,
11.1%), or nearly total pancreatectomy (n/1,
2.2%) with no postoperative mortality. Eight patients
(18%) received adjuvant chemotherapy postopera-
tively. Hospitalization time ranged from 8 to 46 days
(mean time 9/SD/19 9/10.4).
The evaluation of the tumour stage was based on
the pTNM classification (UICC 1997). Differentia-
tion of adenocarcinoma was described as well/mod-
erate or poor grade. Residual tumour classification
(R) was used for assessment of complete tumour
removal. Four margins were assessed pathologically
following precise marking (coloured pins) in the
resection specimen by a surgeon immediately after
the operation: 1) common bile duct, 2) stomach or
duodenum, 3) pancreatic, 4) retroperitoneal. Resec-
tions were classified as microscopically radical (R0),
microscopically non-radical (R1), or macroscopically
non-radical (R2). Follow-up time ranged from 3 to 62
months (median 19 months).
Immunohistochemistry
Tissue material was routinely fixed for 1224 hours in
4% buffered formalin of a volume adequate to the size
of the surgical specimen. Immunohistochemical stain-
ing was performed on processed paraffin-embedded
blocks from representative tumour sections using
monoclonal antibody p27Kip1 (clone SX53G8, Dako-
cytomation), which has been confirmed to recognize
p27kip1 protein exclusively, showing that p27kip1
staining was absent when the antibody was preab-
sorbed with blocking p27kip1 peptide [2931]. Tu-
mour-specific staining not seen in the surrounding
pancreatic or duodenal tissue, with a distinct staining
in the cell nucleus and with markedly less or no
immunoreactivity in the tumour cell cytoplasm, was
considered as a positive cell. Expression of p27Kip1 in
small lymphocytes was used as an internal positive
control of immunostaining. Sections from pancreatic
adenocarcinomas incorporated in the present study
material that underwent the staining procedure, with
omission of the specific antibody, were used as
negative controls.
Quantitative determination of p27kip1 expression
was based on the proportion of p27kip1-positive cells
(p27kip1 labelling index). Cases withB/5% positive
cells were considered negative.
Statistical analysis
The Pearson’s x2 test and Fischer’s exact test were
used to test the association between the p27 labelling
index and clinico-pathological features. The Kaplan-
Meier method and the log rank test were used for
univariate analysis of the relationship between clinico-
pathological features and survival. Multivariate survi-
val analysis was performed with a Cox regression
model entering the following covariates: p27kip1
expression, localization of the tumour (pancreatic
head/uncinate process vs periampullary), size of the
tumour (B/ 3 cm vs ]/3 cm), resection margins status
(R0 vs R1/R2) and differentiation of the tumour (G1/
G2 vs G3).
A p valueB/0.05 was considered to represent a
statistically significant difference. Statistical calcula-
tions were performed using Statistica 6.1 for Windows
(StatSoft Inc., Tulsa, OK, USA).
Results
There were 45 patients with adenocarcinoma of the
pancreatic head region. In 39 of the patients, the
tumour was graded as well/moderately differentiated
(G1/G2). In the remaining six patients, adenocarci-
nomas were poorly differentiated (G3). Distribution
of the pathological stages was as follows: stage I, 14
patients; stage II, 15 patients; stage III, 14 patients,
and stage IV, two patients. Tumour-positive lymph
nodes were detected in 12 patients. The number of
investigated lymph nodes and number of tumour-
positive lymph nodes were as follows (range, mean9/
SD): 116, 4.29/4.0 and 113, 5.69/3.5, respec-
tively. An R0 resection was achieved in 33 of 45 cases.
A resection line involvement was microscopically
recognized in 4 of 45 cases (R1 resection). In eight
patients, the tumour mass was removed incompletely
as assessed macroscopically (R2 resection). Tumour
size ranged from 0.5 to 6.0 cm (mean9/SD/3.59/
1.6). Jaundice before operation was detected in 36
(80%) patients.
Positive p27kip1 expression was detected in 22
tumours (49%), whereas 23 tumours (51%) were
p27kip1-negative (Figure 1). Patients’ gender, age,
tumour size, UICC stage, lymph node metastasis,
preoperative jaundice, differentiation and localization
of the tumour were not related to p27kip1 labelling
index. Among patients with p27kip1-negative tumours
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radical resection (R0) was performed in 20 (86%)
patients, whereas non-radical (R1/R2) resection was
carried out in 3 (14%) patients. In the group of
patients with a p27kip1 labelling index ]/ 5%, an R0
resection was performed in 13 (60%) patients,
whereas non-radical resection was carried out in 9
(40%) patients. A significant relationship was found
between p27kip1-negative tumours and radical resec-
tion (p/0.04; Fisher’s exact test) (Table I).
The 1-, 2- and 3-year survival rates were 72%, 57%
and 43%, respectively. Median survival was 19
months. All deaths were related to the pancreatic
adenocarcinoma. Nineteen patients (42%) died dur-
ing the follow-up period of the study (median 11
Figure 1. Sections of adenocarcinoma of the pancreas. (A) p27Kip1-positive nuclear immunohistochemistry staining. (B) p27Kip1-negative
immunohistochemistry staining. Magnification /200.
Table I. Association between p27kip1 expression and pathological features of carcinomas (Fisher’s exact test).
Variables
Number of patients
with LI B/5% p27kip1
Number of patients
with LI ]/5% p27kip1 Total (n ) p value
Gender
Female 9 6 15
Male 14 16 30 0.5
Age (years)
5/60 15 9 24
/60 8 13 21 0.13
Tumour size (cm)
5/3 10 12 22
/3 13 9 22 0.54
NA 1
Stage
I 9 5 14
II 6 9 15
III 8 6 14
IV 0 2 2 0.26*
Lymph node metastases
Present 7 5 12
Absent 16 17 33 0.7
Jaundice preoperatively
Present 21 15 36
Absent 2 7 9 0.07
Differentiation of the tumour
Well/moderate (G1/G2) 18 21 39
Poor (G3) 5 1 6 0.18
Resection margins
Negative (R0) 20 13 33
Involved (R1/R2) 3 9 12 0.04
Localization of the tumour
Periampullary 9 9 18
Pancreatic head/uncinate process 14 13 27 0.9
LI, labelling index; NA, not assessed.
*Pearson’s x2 test.
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months). Survival of patients with involved margins
(R1/R2) was considerably shorter than that of patients
after R0 resection. On univariate survival analysis,
tumour size (p/0.0002), localization of the tumour
(p/0.0001), differentiation of the tumour (p/
0.006) and involved margins (p/0.01) were signifi-
cant prognostic factors (Table II).
Median survival time in patients with p27kip1-
positive tumours was 19 months, whereas in patients
with p27kip1-negative tumours it was 18 months (p/
0.53) (Figure 2). Even when analysis was stratified
according to localization of the tumour (pancreatic
head/uncinate process vs periampullary), tumour size
or involved margins the survival comparisons of
patients with p27kip1-positive and -negative tumours
did not reveal significant differences.
Multivariate survival analysis included five factors:
p27kip1 expression, localization of the tumour, in-
volved margins, differentiation of the tumour and
tumour size. Multivariate survival analysis revealed
that the localization of the tumour (pancreatic head/
uncinate process vs periampullary) was the only
significant and independent prognosticator (p/0.01,
Cox regression model; Table III). Resection margins
involvement and grade remained nearly significant
prognostic factors (p/0.07 and p/0.09, respectively;
Table III).
Discussion
Tumour suppressor gene p27kip1 is regarded as an
inhibitor of the G1-to-S cell cycle progression by
Table II. Univariate analysis between clinico-pathological features and survival (log rank test).
Variables Patients n (%)
3-year cumulative
survival
Median survival
time (months) p value
Gender
Female 15 (33%) 40% 18
Male 30 (67%) 47% 23 0.9
Age (years)
5/60 24 (53%) 48% 19
/60 21 (47%) 38% 18 0.54
Tumour size (cm)
5/3 22 (49%) 77% 26
/3 22 (49%) 0% 13
NA 1 (2%) 0.0002
Stage
I 14 (31%) 50% 27
II 15 (33%) 46% 16
III 14 (31%) 40% 15
IV 2 (5%) 0% 14 0.25*
Localization of the tumour
Periampullary 18 (40%) 77% 29
Pancreatic head/uncinate process 27 (60%) 14% 10 0.0001
Lymph node metastases
Present 12 (27%) 40% 15 0.41
Absent 33 (73%) 44% 20
Jaundice preoperatively
Present 36 (80%) 39% 19
Not present 9 (20%) 54% 11 0.99
Differentiation of the tumour
Well/moderate (G1/G2) 39 (87%) 50% 19
Poor (G3) 6 (13%) 0 5 0.006
Resection margins
Negative (R0) 33 (73%) 51% 25
Involved (R1/R2) 12 (27%) 0% 10 0.01
p27kip1 labelling index
B/5% 23 (51%) 38% 18
]/5% 22 (49%) 47% 19 0.53
Adjuvant chemotherapy
Surgery/chemotherapy 8 (18%) 25% 14
Surgery alone 37 (82%) 46% 19 0.4
NA, not assessed.
*Cox regression test.
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suppressing the kinase activity of cyclin/cyclin-depen-
dent kinase inhibitor family [26]. Many reports have
validated the utility of p27kip1 as a prognostic and/or
diagnostic marker in breast, colon, lung and prostate
adenocarcinomas [26,3234]. Almost all studies re-
port decreased p27kip1 expression in more aggressive
tumours [26]. Contradictory results come from stu-
dies on p27kip1 prognostic value in pancreatic carci-
noma [27,29,3538].
In the present study a p27kip1 labelling index of
B/5% was found in 51% of the tumours. In other
studies such low p27kip1 expression was demonstrated
in 4170% of tumours [27,29,36].
The loss of p27kip1 expression in the tumour tissue
was correlated with progressive stage of the pancreatic
neoplasm [28,37]. Feakins and Ghaffar and Juuti et
al. were not able to find correlation between p27kip1
expression and tumour stage [27,36]. In two studies
association of low p27kip1 expression and poor tumour
differentiation was reported [27,38], while in the
other reports this phenomenon was not confirmed
[28,36]. In the present study the p27kip1 expression
did not correlate with tumour stage, differentiation of
the tumour or tumour size. These varied results
suggest that association between p27kip1 expression
and clinico-pathological features is weak.
Radical resection is a well established significant
prognosticator [39]. In tumours located in the pan-
creatic head region, we found a significant relation-
ship between negative p27kip1 expression and
microscopically radical resection (R0). Therefore,
low p27kip1 labelling index may identify patients
with pancreatic tumours likely to be removed with
negative margins. Our results are contradictory to
those of Lu et al., who found correlation between low
p27kip1 expression and increasing peripancreatic in-
vasion that reduced the possibility of achieving
complete tumour removal [28]. Previous studies had
shown that low p27kip1 expression may contribute to
tumour development by either increasing the prolif-
eration of cells or decreasing their apoptosis [4042].
On the other hand, findings consistent with ours
have been reported in a series of rectal cancer patients
receiving preoperative chemoradiation [43]. On the
basis of immunohistochemical assessment of residual
tumour in the resected surgical specimen, patients
with rectal cancers exhibiting positive p27kip1 expres-
sion had a fourfold higher risk of recurrence. In that
study positive expression of p27kip1 was an indepen-
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Figure 2. Overall survival of 45 patients with pancreatic adenocarcinoma in relation to tumour p27kip1 expression (p/0.53; log rank test).
Table III. Multivariate analysis for predictive factors in patients
with pancreatic cancer (Cox regression model).
Variables
Risk
ratio (RR) 95% CI p value
Tumour size (cm) 2.848 2.2143.482 0.15
5/3
/3
Localization of the tumour 3.471 2.2104.732 0.01
Periampullary
Pancreatic head/uncinate
process
Differentiation of the tumour 3.232 2.5683.896 0.09
Well/moderate (G1/G2)
Poor (G3)
Resection margins 1.252 1.0681.510 0.07
Negative (R0)
Involved (R1/R2)
p27kip1 labelling index 1.396 1.0001.792 0.62
B/5%
]/5%
CI, confidence intervals.
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dent negative predictor of recurrence-free survival.
The sample size of 45 patients in our study may not be
adequate to detect a discrete difference in survival of
patients with tumours presenting various degrees of
p27kip1 expression that was associated with complete-
ness of tumour removal. This may be a probable
explanation as to why the low p27kip1 expression was
found to be of no prognostic value.
Insignificantly lower 3-year survival rate in the
group of patients following resection and adjuvant
chemotherapy may be explained by the fact that only
patients with more advanced tumours were offered
postoperative treatment.
Our study confirmed well-known prognostic factors
in pancreatic carcinoma such as tumour size, localiza-
tion of the tumour, differentiation of the tumour and
radicality of resection. We found a correlation be-
tween p27kip1 expression and possibility of curative
resection. This relationship, if confirmed in larger
series, may serve for selection of patients who possibly
can benefit from primary radical surgery.
We conclude that p27kip1 has limited overall prog-
nostic utility in resected carcinoma of the pancreatic
head region, but its potential role as a marker of
residual disease needs to be further assessed.
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